Table 3.

Age and multivariable-adjusted association between acrylamide intake and risk of endometrial, ovarian and breast cancer; the Netherlands Cohort Study on diet and cancer (NLCS), 1986 to 1997

Increment per 10 μg acrylamide/dQ1Q2Q3Q4Q5Ptrend
Endometrial cancer
All
Cases/person-years*221/15,83644/3,20240/3,07839/3,09546/3,17552/3,285
HR (95% CI)1.01 (0.90-1.14)1.000.96 (0.61-1.51)0.94 (0.59-1.49)1.09 (0.70-1.70)1.17 (0.76-1.79)0.38
HR (95% CI)§1.04 (0.91-1.19)1.000.95 (0.59-1.54)0.94 (0.56-1.56)1.21 (0.74-1.98)1.29 (0.81-2.07)0.18
Endometrial cancer
Never-smokers
Cases/person-years*, never-smokers150/9,42227/2,11325/1,78629/1,70929/1,88340/1,931
HR (95% CI)1.07 (0.93-1.24)1.001.10 (0.62-1.97)1.36 (0.77-2.40)1.23 (0.70-2.16)1.63 (0.97-2.74)0.07
HR (95% CI)§1.12 (0.95-1.33)1.001.16 (0.63-2.15)1.35 (0.73-2.51)1.30 (0.69-2.46)1.99 (1.12-3.52)0.03
Ovarian cancer
All
Cases/person-years*195/19,03731/3,80339/3,93932/3,59539/3,82354/3,877
HR (95% CI)1.11 (0.99-1.24)1.001.26 (0.77-2.06)1.16 (0.69-1.94)1.33 (0.82-2.18)1.77 (1.11-2.82)0.02
HR (95% CI)1.11 (0.99-1.25)1.001.22 (0.73-2.01)1.12 (0.65-1.92)1.28 (0.77-2.13)1.78 (1.10-2.88)0.02
Ovarian cancer
Never-smokers
Cases/person-years*, never-smokers129/11,44618/2,54027/2,37322/1,99229/2,25033/2,292
HR(95% CI)1.16 (1.00-1.34)1.001.62 (0.87-3.02)1.64 (0.85-3.16)1.90 (1.03-3.50)2.06 (1.13-3.77)0.02
HR(95% CI)1.17 (1.01-1.36)1.001.60 (0.85-3.02)1.64 (0.84-3.19)1.86 (1.00-3.48)2.22 (1.20-4.08)0.01
Breast cancer
All
Cases/person-years*1,350/19,036296/3,732267/3,941257/3,616254/3,877276/3,871
HR (95% CI)0.98 (0.92-1.04)1.000.86 (0.69-1.07)0.91 (0.72-1.14)0.84 (0.67-1.05)0.90 (0.73-1.13)0.37
HR(95% CI)0.99 (0.92-1.06)1.000.80 (0.64-1.02)0.92 (0.72-1.17)0.86 (0.67-1.10)0.93 (0.73-1.19)0.79
Breast cancer
Never-smokers
Cases/person-years*, never-smokers767/11,540159/2,496159/2,379147/2,054144/2,317158/2,294
HR(95% CI)1.01 (0.93-1.09)1.001.06 (0.80-1.41)1.18 (0.88-1.59)1.01 (0.75-1.36)1.10 (0.82-1.47)0.66
HR(95% CI)1.01 (0.93-1.11)1.000.97 (0.72-1.32)1.17 (0.85-1.61)1.00 (0.73-1.38)1.10 (0.80-1.52)0.55
  • NOTE: The numbers of cases and person-years are the numbers that resulted after list-wise deletion of observations with missing values on the selected confounders.

  • * Number of cases that accumulated in the total cohort/person-years at risk of the subcohort.

  • Age-adjusted (same data set as in multivariable-adjusted analyses).

  • Reference category.

  • § Adjusted for: age (y), age at menarche (y), age at menopause (y), age at first childbirth (dummy: nulliparous, 17-19 y, 20-24 y, 25-29 y, ≥ 30 y), parity (n children), duration of oral contraceptives use (y), duration of postmenopausal hormone use (y), BMI (kg/m2), height (cm), current smoking (yes/no), quantity of smoking (cigarettes/d), duration of smoking (n smoking years), non-occupational physical activity (min/d), energy intake (kcal/d), trans-unsaturated fatty acid intake (energy-adjusted; g/d), carbohydrate intake (energy-adjusted; g/d), alcohol consumption (g/d).

  • Adjusted for age (y), age at menarche (y), age at menopause (y), parity (n children), duration of oral contraceptives use (y), duration of postmenopausal hormone use (y), BMI (kg/m2), height (cm), current smoking (yes/no), quantity of smoking (cigarettes/d), duration of smoking (n smoking years), saturated fat intake (energy-adjusted; g/d), trans-unsaturated fatty acid intake (energy-adjusted; g/d).

  • Adjusted for age (y), age at menarche (y), age at menopause (y), age at first childbirth (dummy: nulliparous, 17-19 y, 20-24 y, 25-29 y, ≥30 y), duration of oral contraceptives use (y), duration of postmenopausal hormone use (y), BMI (kg/m2), height (cm), current smoking (yes/no), quantity of smoking (cigarettes/d), duration of smoking (n smoking years), socioeconomic status (four levels of education), energy intake (kcal/d), saturated fat intake (energy-adjusted; g/d), carbohydrate intake (energy-adjusted; g/d), family history of breast cancer (yes/no), history of benign breast disease (yes/no).